said in a regulatory filing.
Zydus Cadila is part of the Cadila Healthcare group.
Droxidopa works by constricting (narrowing) the blood vessels and increasing blood pressure. It is used to treat low blood pressure that causes severe dizziness or a lightheaded feeling.
The company further said that Droxidopa is indicated for use in people with conditions of the nervous system that can cause low blood pressure (such as Parkinson’s disease, multiple system atrophy, autonomic failure, and others).
The newly approved medication will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 312 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.
Shares of Cadila Healthcare were trading 1.51 per cent lower at Rs 460.45 apiece on BSE.
Download The Economic Times News App to get Daily Market Updates & Live Business News.